NEW YORK, Nov. 14 — Eli Mintz, a co-founder of Tel Aviv, Israel-based Compugen, was named chairman of the company’s wholly owned US subsidiary, Compugen, the company said on Wednesday.
Mintz will continue to serve on the parent company’s board of directors and will devote about forty percent of his time to the new chairman position.
The company was founded in 1993 in order to develop bioinformatics hardware, and now focuses on computational genomics and proteomics. Its US subsidiary is based in Jamesburg, NJ.
Applera has appointed Michael Albin vice president of strategic technologies, the firm announced on Nov. 8. Albin, who has been with the company since 1989, will assess technology opportunities that involve multiple Applera business units.
He will provide technical direction, recommend collaborations and help to guide the company’s strategic direction, a company executive said in a statement. The changes makes Albin a member of the company’s executive committee.
Prior to this position, Albin was vice president for science and technology at Applied Biosystems, where he oversaw technology assessment, R&D, early stage development and was involved in business development.
Miguel Rios, Jr., has been appointed interim president and CEO of the National Center for Genome Resources, the center announced on Nov. 8.
Rios, a member of the center's board of directors since 1995, founded ORION International Technologies in 1985 in Albuquerque and is ORION's CEO.
He replaces Stephen C. Joseph, who resigned as president and CEO. It was not immediately clear why he resigned. He joined NCGR in March 1999.
Rios will guide NCGR's research and development programs in bioinformatics, according to the center.
Neurome has appointed noted neuroscientists Leslie Iversen and Paul Greengard to its scientific advisory board, the company said in statements released on Nov. 5 and Nov. 8.
Iversen is internationally known for his research into neurotransmitters and neuropeptides in the mammalian central nervous system. His work has also been applied to the diagnosis and treatment of schizophrenia and Alzheimer’s disease.
Iversen is professor of pharmacology at the Royal postgraduate Medical School, Hammersmith Hospital, London. He is also a visiting professor in the department of pharmacology at the University of Oxford, and director of the Wolfson Centre for Age-Related Diseases at London’s King’s College.
Greengard, a 2000 Nobel Laureate in Physiology and Medicine, is recognized for his work in the role of dopamine in the central nervous system, and his exploration of signal transduction and the molecular mechanisms of neurotransmission. He is Astor Professor at Rockefeller University, and head of the university’s Laboratory of Molecular and Cellular Neuroscience.
Neurome, a San Diego-based company, develops gene expression databases to aid in understanding brain function and disease.
Strand Genomics, a bioinformatics company based in Bangalore, India, announced that Kris Venkat has been appointed to its board of directors, where he will provide strategic advice on business matters, the firm said on Nov. 2.
Venkat, who is currently chairman of Morphochem, comes to Strand with experience working with Merck & Co., Transvivo, Automated Cell, and Sundari Enterprises. He is also the co-founder and chairman of Accentua Pharma and Juelich Enzyme Products, both based in Germany.
Promoted? Changing jobs? GenomeWeb wants to know. Help us keep track of you by e-mailing us at [email protected].
PEOPLE, a roundup of personnel comings and goings in the genomics sector, appears every Wednesday.